{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:39:00Z","timestamp":1784299140263,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,7,14]],"date-time":"2016-07-14T00:00:00Z","timestamp":1468454400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s10557-016-6674-1","type":"journal-article","created":{"date-parts":[[2016,7,14]],"date-time":"2016-07-14T10:05:03Z","timestamp":1468490703000},"page":"393-398","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacological Management of Chronic Stable Angina: Focus on Ranolazine"],"prefix":"10.1007","volume":"30","author":[{"given":"Giuseppe M. C.","family":"Rosano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Volterrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,14]]},"reference":[{"key":"6674_CR1","doi-asserted-by":"crossref","unstructured":"Task Force Members, Montalescot G, Sechtem U, Achenbach S, et al 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949\u20133003.","DOI":"10.1093\/eurheartj\/eht296"},{"key":"6674_CR2","unstructured":"Scarborough P, Bhatnagar P, Wickramasinghe K, Smolina K, Mitchell C, Rayner M. Coronary heart disease statistics 2010. British Heart Foundation 2010."},{"issue":"25","key":"6674_CR3","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.2174\/138161208786071317","volume":"14","author":"GM Rosano","year":"2008","unstructured":"Rosano GM, Fini M, Caminiti G, Barbaro G. Cardiac metabolism in myocardial ischemia. Curr Pharm Des. 2008;14(25):2551\u201362.","journal-title":"Curr Pharm Des"},{"issue":"6","key":"6674_CR4","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/j.1472-8206.2010.00895_2.x","volume":"24","author":"GM Rosano","year":"2010","unstructured":"Rosano GM, Collins P. Gender differences in treatment of cardiovascular disease: a task force on gender of the ESC proposal on gender specific studies in cardiovascular pharmacology. Fundam Clin Pharmacol. 2010;24(6):662\u20133.","journal-title":"Fundam Clin Pharmacol"},{"key":"6674_CR5","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa070829","volume":"356","author":"W Boden","year":"2007","unstructured":"Boden W, O\u2018Rourke R, Teo K, et al. Optimal medical therapy with or without PCI for stable coronary disease: the COURAGE trial. N Engl J Med. 2007;356:1503\u201316.","journal-title":"N Engl J Med"},{"key":"6674_CR6","unstructured":"Summary of Product Characteristics. Ranexa\u00ae (ranolazine). http:\/\/www.medicines.org.uk\/EMC\/medicine\/21402\/SPC\/Ranexa%20prolonged-release%20tablets\/"},{"issue":"suppl A","key":"6674_CR7","first-page":"A13","volume":"6","author":"L Belardinelli","year":"2004","unstructured":"Belardinelli L, Antzelevitch C, Fraser H. Inhibition of late (sustained\/persistent) sodium current: a potential drug target to reduce intracellular sodium-dependent calcium overload and its detrimental effects on cardiomyocyte function. Eur Heart J. 2004;6(suppl A):A13\u20137.","journal-title":"Eur Heart J"},{"key":"6674_CR8","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1113\/jphysiol.1996.sp021772","volume":"497","author":"YK Ju","year":"1996","unstructured":"Ju YK, Saint DA, Gage PW. Hypoxia increases persistent sodium current in rat ventricular myocytes. J Physiol. 1996;497:337\u201347.","journal-title":"J Physiol"},{"key":"6674_CR9","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1161\/01.RES.71.5.1231","volume":"71","author":"AI Undrovinas","year":"1992","unstructured":"Undrovinas AI, Fleidervish IA, Makielski JC. Inward sodium current at resting potentials in single cardiac myocytes induced by the ischemic metabolite lysophosphatidylcholine. Circ Res. 1992;71:1231\u201341.","journal-title":"Circ Res"},{"key":"6674_CR10","first-page":"H1034","volume":"266","author":"J Wu","year":"1994","unstructured":"Wu J, Corr PB. Palmitoyl carnitine modifies sodium currents and induces transient inward current in ventricular myocytes. Am J Phys. 1994;266:H1034\u201346.","journal-title":"Am J Phys"},{"key":"6674_CR11","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1113\/jphysiol.1997.sp022048","volume":"500","author":"CA Ward","year":"1997","unstructured":"Ward CA, Giles WR. Ionic mechanism of the effects of hydrogen peroxide in rat ventricular myocytes. J Physiol. 1997;500:631\u201342.","journal-title":"J Physiol"},{"key":"6674_CR12","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1540-8167.2001.00218.x","volume":"12","author":"B Huang","year":"2001","unstructured":"Huang B, El Sherif T, Gidh-Jain M, et al. Alterations of sodium canne kinetics and gene expression in the postinfarction remodeled myocardium. J Cardiovasc Electrophysiol. 2001;12:218\u201325.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"6674_CR13","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1161\/01.RES.68.5.1250","volume":"68","author":"E Murphy","year":"1991","unstructured":"Murphy E, Perlman M, London RE, Steenbergen C. Amiloride delays the ischemia-induced rise in cytosolic free calcium. Circ Res. 1991;68:1250\u20138.","journal-title":"Circ Res"},{"key":"6674_CR14","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/00005344-200408000-00008","volume":"44","author":"Y Song","year":"2004","unstructured":"Song Y, Shryock JC, Wu L, Belardinelli L. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in Guinea pig ventricular myocytes. J Cardiovasc Pharmacol. 2004;44:192\u20139.","journal-title":"J Cardiovasc Pharmacol"},{"key":"6674_CR15","doi-asserted-by":"crossref","first-page":"178A","DOI":"10.1016\/S0735-1097(04)90758-9","volume":"43","author":"AI Undrovinas","year":"2004","unstructured":"Undrovinas AI, Undrovinas NA, Belardinelli L. Ranolazine inhibits late sodium current in isolated left ventricular myocytes of dogs with heart failure. J Am Coll Cardiol. 2004;43:178A.","journal-title":"J Am Coll Cardiol"},{"key":"6674_CR16","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1161\/01.CIR.0000139333.83620.5D","volume":"110","author":"C Antzelevitch","year":"2004","unstructured":"Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004;110:904\u201310.","journal-title":"Circulation"},{"issue":"abstract suppl.","key":"6674_CR17","first-page":"414","volume":"26","author":"H Fraser","year":"2005","unstructured":"Fraser H, Belardinelli L, Wang L, et al. Inhibition of late INa by ranolazine reduces Ca2 overload and LV mechanical dysfunction in ejecting rat hearts. Eur Heart J. 2005;26(abstract suppl.):414.","journal-title":"Eur Heart J"},{"key":"6674_CR18","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/cvr\/28.8.1231","volume":"28","author":"MR Gralinski","year":"1994","unstructured":"Gralinski MR, Black SC, Kilgore KS, et al. Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart. Cardiovasc Res. 1994;28:1231\u20137.","journal-title":"Cardiovasc Res"},{"key":"6674_CR19","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1211\/0022357001774381","volume":"52","author":"K Maruyama","year":"2000","unstructured":"Maruyama K, Hara A, Hashizume H, et al. Ranolazine attenuates palmitoyl-L-carnitine induced mechanical and metabolic derangement in the isolated, perfused rat heart. J Pharm Pharmacol. 2000;52:709\u201315.","journal-title":"J Pharm Pharmacol"},{"key":"6674_CR20","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jacc.2003.11.045","volume":"43","author":"BR Chaitman","year":"2004","unstructured":"Chaitman BR, Skettino SL, Parker JO, Ramos H-VA, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43:1375\u201382.","journal-title":"J Am Coll Cardiol"},{"key":"6674_CR21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.291.3.309","volume":"291","author":"BR Chaitman","year":"2004","unstructured":"Chaitman BR, Pepine CJ, Parker JO, for the Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. A randomized controlled trial. JAMA. 2004;291:309\u201316.","journal-title":"JAMA"},{"key":"6674_CR22","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jacc.2006.05.044","volume":"48","author":"PH Stone","year":"2006","unstructured":"Stone PH, Gratsiansky NA, Blokhin A, Huang I-Z, Meng L, for the ERICA Investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (efficacy of ranolazine in chronic angina) trial. J Am Coll Cardiol. 2006;48:566\u201375.","journal-title":"J Am Coll Cardiol"},{"key":"6674_CR23","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1001\/jama.297.16.1775","volume":"297","author":"DA Morrow","year":"2007","unstructured":"Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, for the MERLIN-TIMI 36 Trial Investigators, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes. The MERLIN-TIMI 36 Randomized Trial. JAMA. 2007;297:1775\u201383.","journal-title":"JAMA"},{"issue":"20","key":"6674_CR24","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.jacc.2013.02.011","volume":"61","author":"M Kosiborod","year":"2013","unstructured":"Kosiborod M, Arnold SV, Spertus JA, et al. The TERISA study (type 2 diabetes evaluation of ranolazine in subjects with chronic stable angina). J Am Coll Cardiol. 2013;61(20):2038\u201345.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"6674_CR25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1161\/CIRCULATIONAHA.115.019768","volume":"133","author":"KP Alexander","year":"2016","unstructured":"Alexander KP, Weisz G, Prather K, James S, Mark DB, Anstrom KJ, Davidson-Ray L, Witkowski A, Mulkay AJ, Osmukhina A, Farzaneh-Far R, Ben-Yehuda O, Stone GW, Ohman EM. Effects of ranolazine on angina and quality of life after percutaneous coronary intervention with incomplete revascularization: results from the ranolazine for incomplete vessel revascularization (RIVER-PCI) trial. Circulation. 2016;133(1):39\u201347.","journal-title":"Circulation"},{"issue":"4","key":"6674_CR26","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ijcard.2013.08.131","volume":"169","author":"G Savarese","year":"2013","unstructured":"Savarese G, Rosano G, D\u2019Amore C, et al. Effects of ranolazine in symptomatic patients with stable coronary artery disease. A systematic review and meta-analysis. Int J Cardiol. 2013;169(4):262\u201370.","journal-title":"Int J Cardiol"},{"issue":"5","key":"6674_CR27","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/dom.12629","volume":"18","author":"J Pettus","year":"2016","unstructured":"Pettus J, McNabb B, Eckel RH, Skyler JS, Dhalla A, Guan S, Jochelson P, Belardinelli L, Henry RH. The effect of ranolazine on glycemic control in patients with type 2 diabetes treated with either glimepiride or metformin. Diabetes Obes Metab. 2016;18(5):463\u201374.","journal-title":"Diabetes Obes Metab"},{"key":"6674_CR28","doi-asserted-by":"crossref","unstructured":"Hidalgo-Vega A, Ramos-Go\u00f1i JM, Villoro R. Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain. Eur J Health Econ. 2013;15(9):917\u201325.","DOI":"10.1007\/s10198-013-0534-8"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-016-6674-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-016-6674-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-016-6674-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T04:16:37Z","timestamp":1568175397000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-016-6674-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,14]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["6674"],"URL":"https:\/\/doi.org\/10.1007\/s10557-016-6674-1","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,14]]}}}